Filing Flows › Maravai Lifesciences Holdings (MRVI) › R&D spending
Maravai Lifesciences Holdings (MRVI) R&D spending by quarter
Maravai Lifesciences Holdings' R&D spending was $3.4M in Q3 2026 (third quarter 2026), -8% from Q2 2026. Over the last 7 quarters it ranged from $3.4M (Q3 2026) to $4.9M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.4M | -8% | -12% |
| Q2 2026 | $3.7M | -5% | -24% |
| Q1 2026 | $3.9M | +3% | -20% |
| Q4 2025 | $3.8M | -1% | — |
| Q3 2025 | $3.8M | -21% | — |
| Q2 2025 | $4.9M | -0.1% | — |
| Q1 2025 | $4.9M | — | — |
Q3 2026 at a glance
Maravai Lifesciences Holdings, Q3 2026: revenue $45.9M (+10% year over year), operating margin -45.0%, net loss $24.0M, operating cash flow $5.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Maravai Lifesciences Holdings' R&D spending?
Maravai Lifesciences Holdings' R&D spending was $3.4M in Q3 2026 (third quarter 2026), -8% from Q2 2026.
How has Maravai Lifesciences Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $3.4M (Q3 2026) to $4.9M (Q1 2025).
Q3 2026 results → · How Maravai Lifesciences Holdings makes money →